Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic
chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary
endpoint is actuarial one-year survival.
The secondary objectives are:
- To evaluate the local tumor response in patients treated with the above regimen.
- To characterize the safety of the above regimen.